| Prev Close: | 27.97 |
|---|---|
| Open: | 28.24 |
| Bid: | 27.98 x 100 |
| Ask: | 28.53 x 100 |
| 1y Target Est: | 31.38 |
| Beta: | 0.69 |
| Next Earnings Date: | 30-Jul-13 |
| Day's Range: | 28.08 - 28.30 |
|---|---|
| 52wk Range: | 22.00 - 31.15 |
| Volume: | 32,211,183 |
| Avg Vol (3m): | 62,656,100 |
| Market Cap: | 199.53B |
| P/E (ttm): | 13.47 |
| EPS (ttm): | 2.09 |
| Div & Yield: | 0.96 (3.40%) |
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Midday Glance: Pharmaceuticals companiesAP(Mon 1:24PM EDT)
- Four Robust Investments in Dialysis and Diabetesat Motley Fool(Mon 1:17PM EDT)
- Today's Stocks Driving Success For The Drugs Industryat TheStreet(Mon 1:03PM EDT)
- Valeant Pharmaceuticals (VRX) Challenges Heavy-R&D; Model Among Pharmaceuticals and Maximizes Returns on Investments While Lowering CostsWall Street Transcript(Mon 11:55AM EDT)
- Mylan’s $1.6 Billion Strides Deal Delayed, Newspaper Saysat Bloomberg(Mon 11:37AM EDT)
- Three Good Companies With Unloved Stocksat Motley Fool(Mon 10:41AM EDT)
- Early Glance: Pharmaceuticals companiesAP(Mon 10:32AM EDT)
- SAC’s Cohen Said to Remain Under Investigationat Bloomberg(Sun, Jul 7)
- The Dow's 5 Most Hated Stocksat Motley Fool(Sun, Jul 7)
- Inhaled Insulin: Biotech Triumph or Future Flop?at Motley Fool(Sun, Jul 7)
- Is Merck Destined for Greatness?at Motley Fool(Sun, Jul 7)
- Fight Rising Rates With This Dividend ETFETF Trends(Sat, Jul 6)
- Impax Challenges Toviaz PatentZacks(Fri, Jul 5)
- Pfizer Inc (PFE): Today's Featured Drugs Winnerat TheStreet(Fri, Jul 5)
- Symplmed Wins Rights from XOMAZacks(Fri, Jul 5)
Press Releases
- Lpath to Present at the 2013 JMP Healthcare Conference on July 9Marketwired(Wed, Jul 3)
- Acura Pharmaceuticals Provides Update on Partnership With PfizerMarketwired(Mon, Jul 1)
- Eliquis® (apixaban) Demonstrated Comparable Efficacy and Significantly Lower Rates of Major Bleeding in Patients Compared to Current Standard of Care for the Treatment of Acute Venous ThromboembolismBusiness Wire(Sun, Jun 30)
Reports
- PFE - Pfizer Inc - Rated a Hold - Company Analysis and ASR Ranking ReportAlpha Street Research(Jul 8)
- PFE: Due Diligence Review: Forensic Earnings and ValuationNew Constructs, LLC(Jul 8)
- Thomson Reuters Stock Report - PFIZER INC. (PFE-N)Thomson Reuters Stock Report(Jul 8)